Weight Loss Drugs: A Double-Edged Sword for Lean Mass

Eli Lilly's GLP-1 drug tirzepatide shows greater weight loss compared to Novo Nordisk's semaglutide, but with more muscle and connective tissue loss. Study findings reveal tirzepatide users experience greater lean body mass reduction, highlighting the need for careful consideration of drug choices. Both drugs link exercise tolerance decrease with lean mass loss.

In a recent study, Eli Lilly's GLP-1 drug tirzepatide, marketed as Zepbound and Mounjaro, was shown to achieve more substantial weight loss than Novo Nordisk's semaglutide, known as Wegovy and Ozempic. However, researchers noted that tirzepatide users experienced significant loss of muscle and connective tissues.

The analysis, conducted by Massachusetts-based firm nference, involved data from roughly 1,800 patients using tirzepatide and 6,200 using semaglutide. Results indicated that tirzepatide patients lost an average of 1.1% more lean body mass after three months and 2% after 12 months of continuous use compared to their semaglutide counterparts.

Study leader Venky Soundararajan emphasized that patients should not make simplistic decisions based solely on weight loss metrics. Factors such as decreased exercise tolerance and preexisting musculoskeletal pain were linked to greater lean body mass loss, calling for a nuanced approach in drug selection.